How internal circadian clocks in neurons encode external daily rhythms of excitability

A mechanism through which circadian clocks in neurons encode external daily rhythms of excitability allows pacesetter neurons to communicate with the rest of the body via electrical impulses, with possible implications in understanding and treating mood disorders.

karen gamble 2016Karen Gamble, Ph.D.Molecular clocks in cells throughout the body control many physiologic changes in a 24-hour day/night circadian rhythm — among them the timing of sleep and wakefulness.

The master pacesetter for those clocks resides in a tiny part of the human brain, where about 42,000 nerve cells spontaneously and independently maintain a 24-hour cycle through rhythmic internal surges and falls of biochemical signals. But nerve cells communicate to each other via external electrical impulses. So how do those internal biochemical clock signals get turned into changes in external electrical firing activity, the activity that spreads the pacesetter timing in those 42,000 cells throughout the brain and the rest of the body?

Researchers led by Karen Gamble, Ph.D., associate professor in the University of Alabama at Birmingham Department of Psychiatry and Behavioral Neurobiology, have identified a key mechanism linking the two in a paper published today in Nature Communications.

It involves the activity of a kinase enzyme called GSK3 that changes the excitability — a technical term for the likelihood of a nerve cell to fire an electrical impulse — of those neurons. Identification of this role for GSK3 raises clinical interest because GSK3 is the target of lithium and other mood-stabilizing drugs used to treat bipolar disorder. Also, the sodium channels that were found to be regulated by GSK3 are the target of riluzole, a drug used to treat amyotropic lateral sclerosis, known as ALS or Lou Gehrig’s disease, as well as anxiety disorders and depression.

Thus, an understanding of how the GSK3 enzyme alters excitability may offer new approaches to understand and treat mood disorders.

“GSK3 is basically a linking molecule that can connect molecular changes inside the cell to excitability,” Gamble said.

The intrinsic clock resides in the suprachiasmatic nuclei of the hypothalamus, or SCN, which sits at the bottom of the brain. In mouse experiments, it can be visualized by linking one of the molecules of the biochemical internal clock in the SCN to a jellyfish green fluorescent protein. When a slice of SCN — which measures just one-thirty-second of an inch wide — is grown in tissue culture, the cells produce fluorescence, once a day, for weeks, like a very slow lighthouse flashing a constant rhythm. At the same time, the GSK3 activity in the cells rises and falls on a 24-hour cycle. The external behavior of the SCN cells also rises and falls every 24 hours — the nerve cells fire rapid electrical impulses in the day and are quiet at night.

GSK3, or glycogen synthase kinase 3, turns out to be a key to those electrical changes.

Because its activity changes with the circadian rhythm, targeting GSK3 with drugs will have different effects depending on the time of day the drug is taken. This daily timing of treatments to maximize health benefits and minimize side effects is called chronotherapeutics.

Mechanistic details

The Gamble team, also led by first author Jodi Paul, Ph.D., UAB Department of Psychiatry and Behavioral Neurobiology, did experiments using inhibitors of GSK3 and the sodium channels, and also using mice whose GSK3 activity never turns off. They found that GSK3 activity regulates a certain movement of sodium ions across the membrane of SCN nerve cells, a flow that is called the persistent sodium current. Flows of positive or negative ions such as sodium, potassium and calcium across the membrane are basically electrical currents.

The model also successfully predicted that the increased excitability resulting from the increased persistent sodium current is caused by another change across the nerve cell membrane — suppression of the action potential after-hyperpolarization.

The persistent sodium current is a weak, slowly developing current, but changes in its magnitude can make the nerve cell more likely to fire the massive flow of ions that creates the electrical impulses to signal other nerves. Such electrical impulses — known as action potentials — are the signals the brain uses to convey, receive and analyze information.

Until now, the persistent sodium current has largely been overlooked as a potential contributor to the circadian modulation of rhythmic firing. This study is the first to show that the persistent sodium current is greater in magnitude during the day versus at night.

Experimental results from the SCN were fed into a mathematical model created by colleagues at the University of Michigan. The model unexpectedly predicted that, as a change in persistent sodium current increased the firing rate of neurons, it would not alter another measure of the electrical state of neurons called the resting membrane potential, which is the balance of ions inside and outside of the cell. This prediction was experimentally confirmed, and it is important because changes in the resting membrane potential act as a feedback to shift the 24-hour clock forward or back in time, such as resetting the circadian clock after a jet-lag flight to a different global time zone.

The model also successfully predicted that the increased excitability resulting from the increased persistent sodium current is caused by another change across the nerve cell membrane — suppression of the action potential after-hyperpolarization.

Besides Gamble and Paul, authors of the paper, “GSK3 regulation of persistent Na+ current encodes daily rhythms of excitability,” are Daniel DeWoskin and Daniel B. Forger, Department of Mathematics, University of Michigan; and Laura J. McMeekin and Rita M. Cowell, UAB Department of Psychiatry and Behavioral Neurobiology.

This work was supported by National Institutes of Health grants NS082413 and NS086282, Air Force Office of Scientific Research grant FA 9550-14-1-0065, and Human Frontiers of Science Program Grant RPG 24/2012.